HOME >> MEDICINE >> NEWS
Even in an era of HAART Drugs, HIV patients are vulnerable to opportunistic infections

line therapy. They may not be effective, however, in patients who have previously had treatment with this class of drugs. Patients who are responding to HAART may be doing well enough that they don't need prophylaxis, she said.

"The risks versus benefits must be carefully evaluated. We want to protect patients from MAC, but we also want to prevent them from developing resistance to antibiotics," said Aberg, who is a UCSF assistant professor of medicine and also treats patients at San Francisco General.

In the pre-HAART era, macrolides were standard treatment as prevention therapy against MAC infection in AIDS patients whose CD4+ counts were below 75, according to Aberg. Now with HAART, many patients may have CD4+ counts that are higher.

The main conclusion from study findings, she said, is that careful consideration should be given to continuing use of macrolides for MAC prophylaxis when CD4+ counts have increased and to using macrolides for infection treatment if a patient has been on a macrolide previously.

Both research studies were supported by grants from the NIH UCSF Center for AIDS Research and the UC Universitywide AIDS Research Program,

In addition, the CMV retinitis study received a grant from Research to Prevent Blindness, Inc., and the macrolide bacterial resistance study received support from Abbott Laboratories.


'"/>

Contact: Corinna Kaarlela
ckaarlela@pubaff.ucsf.edu
415-476-3804
University of California - San Francisco
27-Sep-1999


Page: 1 2 3

Related medicine news :

1. Most episodes of HIV blips not clinically significant in patients receiving HAART
2. Multiple characteristics of HAART affect adherence
3. Researchers examine the use of antiretroviral therapy among injection drug users with HIV infection: Study suggests addiction treatment and health care contribute to HAART enrollment
4. ICAAC highlight: MAC prophylaxis can be safely discontinued in HIV-infected patients who respond to HAART
5. Old Drugs, New Tricks
6. Hormonal treatment improves survival in high-risk prostate cancer patients
7. Study finds that coordinating care of chronically ill patients does not increase liability
8. Mouse model reveals potential way to reduce cardiac deaths in kidney patients
9. Optical technique identifies vulnerable plaques in cardiac patients
10. NHS target driven culture is failing patients
11. Cardiac deaths peak in sleep hours for patients with sleep apnea

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/13/2016)... Lake City, Utah (PRWEB) , ... February 13, 2016 , ... When an Au ... Host Parents aren’t always sure what they are in for and they are often worried ... are more than they were hoping for. This year’s Au Pair of the Year winner’s ...
(Date:2/12/2016)... LA (PRWEB) , ... February 12, 2016 , ... The ... St. Landry and Evangeline Parishes. The purpose of these scholarships is to encourage ... encourage those individuals to seek employment within these two parishes. , “We have ...
(Date:2/12/2016)... (PRWEB) , ... February 12, 2016 , ... Each year, ... will be held in Anaheim, CA at the Anaheim Convention Center. Almost 10,000 physical ... see new therapy products in action, learn more about their chosen field and network ...
(Date:2/12/2016)... Miami, FL (PRWEB) , ... February 12, 2016 ... ... Workspace as a Service (WaaS), today announced the integration of Clarity Intelligence Platform ... itopia’s channel partners to offer real-time business intelligence (BI) to their small and ...
(Date:2/12/2016)... Colorado (PRWEB) , ... February 12, 2016 , ... Vail ... ASC Industry Physician Leaders to Know in 2016 . The list consists of physicians ... nominated physicians to establish this list. , An Ambulatory Surgery Center, also known ...
Breaking Medicine News(10 mins):
(Date:2/12/2016)... 12, 2016  Sequent Medical, Inc. announced today that ... evaluate the safety and effectiveness of the WEB™ Aneurysm ... intracranial aneurysms.  Prof Laurent Spelle , MD, Head ... Paris, France and Principal Investigator of the ... France and Germany.  Although patients with ruptured ...
(Date:2/12/2016)... 12, 2016  Eli Lilly and Company (NYSE: LLY ... Alimta® (pemetrexed disodium) vitamin regimen patent would not presently be ... France , Italy and ... product only with dextrose solution.  --> ... Court of Appeal held that Lilly,s patent would be indirectly ...
(Date:2/12/2016)... WILMINGTON, North Carolina , 12 februari ... Laboratories, Inc. (AAI/CML), een toonaangevende leverancier van ... farmaceutische en biotechnologische industrieën, kondigt vandaag een ... en mogelijkheden op haar locatie in ... in vraag heeft geleid tot meerdere recente ...
Breaking Medicine Technology:
Cached News: